terf2ip Antibody

What is TERF2IP and why are antibodies against it important for research?

TERF2IP (Telomeric Repeat Binding Factor 2 Interacting Protein), also known as RAP1, is a 399 amino acid protein with a molecular weight of 44.3 kDa that serves dual functions as a telomere regulator and transcription factor . It's localized in both the nucleus and cytoplasm and is ubiquitously expressed across various tissues . TERF2IP antibodies are crucial for studying telomere biology, cellular senescence, and cancer progression. As part of the shelterin complex, TERF2IP works with TERF2/TRF2 to protect telomere ends and control DNA topoisomerases (TOP1, TOP2A, TOP2B) during telomere replication . Its dysregulation has been linked to senescence by hampering DNA repair and cell proliferation . Methodologically, these antibodies enable researchers to track TERF2IP expression, localization, interactions, and functional effects across multiple experimental systems.

Which applications are most commonly supported by commercial TERF2IP antibodies?

Commercial TERF2IP antibodies primarily support Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC), and Enzyme-Linked Immunosorbent Assay (ELISA) . Western Blot is the most widely used application, with recommended dilutions typically ranging from 1:2000-1:12000 . For immunoprecipitation, using 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate is standard practice . Immunofluorescence applications usually employ a 1:1000 dilution of primary antibody followed by fluorophore-conjugated secondary antibodies (such as Alexa Fluor 555 at 1:4000) . For IHC applications, dilutions between 1:50-1:500 are recommended, with antigen retrieval using TE buffer at pH 9.0 for optimal results . Methodologically, researchers should always validate each antibody for their specific application and experimental system.

How should I validate TERF2IP antibodies for experimental use?

Comprehensive validation of TERF2IP antibodies requires a multi-step approach:

• Positive Controls: Test antibodies on cell lines with confirmed TERF2IP expression, such as HeLa, MCF-7, NIH/3T3, Jurkat, and K-562 cells .

• Knockdown Validation: Implement siRNA-mediated TERF2IP knockdown as described in published protocols, where cells are transfected with TERF2IP-targeting siRNAs using Lipofectamine 2000, followed by protein extraction 48 hours post-transfection .

• Western Blot Validation: Confirm detection of a single band at the expected molecular weight (canonical 44.3 kDa, though observed at 65-69 kDa in some systems) .

• Loading Controls: Use GAPDH for cytoplasmic fractions and histone H3 for nuclear fractions when analyzing subcellular distribution .

• Subcellular Localization: Verify both nuclear and cytoplasmic localization patterns through immunofluorescence, consistent with known TERF2IP distribution .

• Cross-Reactivity Assessment: Test the antibody's specificity across human, mouse, and rat samples if working with these species .

This methodical validation ensures experimental reliability and reproducibility.

What are the optimal protocols for Western blot analysis using TERF2IP antibodies?

For optimal Western blot detection of TERF2IP, follow this detailed protocol:

Sample Preparation:

• Extract proteins using RIPA lysis buffer supplemented with protease inhibitor cocktail, PMSF, and NEM

• Quantify protein concentration and prepare 20-40 μg per lane

Gel Electrophoresis and Transfer:

• Separate proteins via SDS-PAGE (8-12% gel recommended)

• Transfer to PVDF membrane at 100V for 1-2 hours in transfer buffer

Antibody Incubation:

• Block membrane with 5% nonfat milk in PBST for 1 hour at room temperature

• Incubate with primary TERF2IP antibody (1:2000-1:12000) overnight at 4°C

• Wash 3× with PBST, 5 minutes each

• Incubate with HRP-conjugated secondary antibody for 1 hour at room temperature

• Wash 3× with PBST, 5 minutes each

Detection:

• Develop using ECL chemiluminescent reagent (ClarityTM or ClarityTM Max recommended)

• Expected molecular weight: canonical 44.3 kDa, though observed at 65-69 kDa in some experimental systems

Controls:

• Include GAPDH as loading control for whole cell/cytoplasmic fractions

• Use histone H3 for nuclear fractions if performing subcellular analysis

• Include TERF2IP-depleted sample as negative control when possible

How can I optimize immunoprecipitation experiments with TERF2IP antibodies?

For successful TERF2IP immunoprecipitation, implement this methodological approach:

Lysate Preparation:

• Harvest cells at 80-90% confluence

• Lyse cells using RIPA buffer containing protease inhibitors

• Use 1000 μg of total protein for optimal pulldown efficiency

Pre-clearing (Optional but Recommended):

• Incubate lysate with Protein A/G beads for 1 hour at 4°C

• Centrifuge and collect supernatant

Immunoprecipitation:

• Add TERF2IP antibody (0.5-4.0 μg for 1.0-3.0 mg lysate)

• Incubate overnight at 4°C with gentle rotation

• Add pre-washed Protein A/G beads

• Incubate for 2-4 hours at 4°C

• Wash beads 4-5 times with cold wash buffer

Analysis:

• Elute by boiling in SDS sample buffer

• Analyze by Western blot, probing with TERF2IP antibody or antibodies against interaction partners

• Include 5% input as reference control

• Quantify band intensities using ImageJ software

This protocol has been successfully applied to detect interactions between TERF2IP and partners like MLL2 and p65 .

What is the recommended protocol for immunofluorescence detection of TERF2IP?

For high-quality immunofluorescence visualization of TERF2IP:

Sample Preparation:

• Culture cells on coverslips to 60-70% confluence

• Fix with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 for 10 minutes

Blocking and Antibody Incubation:

• Block with 1% BSA in PBS for 1 hour

• Incubate with TERF2IP antibody (1:1000 dilution) overnight at 4°C

• Wash 3× with PBS to remove unbound antibody

• Incubate with fluorescent secondary antibody (Alexa Fluor 555, 1:4000) for 2 hours

• Wash 3× with PBS

Nuclear Staining and Mounting:

• Counterstain nuclei with DAPI

• Mount with 70% glycerol or appropriate mounting medium

Imaging and Analysis:

• Image using confocal microscopy (Zeiss ApoTome.2 or similar)

• Analyze signal intensity and localization using ImageJ software

• Expected pattern: Both nuclear and cytoplasmic localization

For co-localization studies with interaction partners (e.g., MLL2, p65), follow the sequential staining protocol detailed in the literature .

How can TERF2IP antibodies be used to study cellular senescence mechanisms?

TERF2IP antibodies are instrumental in senescence research through these methodological approaches:

Senescence-Associated Secretory Phenotype (SASP) Analysis:

• Monitor TERF2IP expression changes during senescence using Western blot

• Correlate with established senescence markers like p16 and p21

• Compare TERF2IP phosphorylation status between young and senescent cells

Transcriptome Analysis:

• Perform TERF2IP knockdown via siRNA

• Conduct unbiased transcriptome analysis to identify TERF2IP-regulated genes during senescence

• Generate differential expression profiles using tools like Qlucore Omics Explorer

Protein-Protein Interaction Studies:

• Use co-immunoprecipitation to detect changes in TERF2IP interaction partners during senescence

• Focus on interactions with other shelterin components (especially TERF2/TRF2)

• Map interaction domains using truncated TERF2IP constructs (133-191 aa, 1-282 aa, full length)

Subcellular Localization:

• Track TERF2IP localization changes during senescence progression using immunofluorescence

• Co-stain with senescence markers and telomere-associated proteins

• Quantify nuclear/cytoplasmic distribution ratios at different senescence stages

These approaches have revealed that dysregulation of shelterin proteins including TERF2IP contributes to senescence by hampering DNA repair and cell proliferation .

What methodologies combine TERF2IP antibodies with functional assays in cancer research?

In cancer research, TERF2IP antibodies can be integrated with functional assays through these methodological approaches:

Expression Analysis in Tumor Samples:

• Use immunohistochemistry with TERF2IP antibodies on cancer tissue microarrays

• Compare expression between tumor and adjacent normal tissues

• Correlate with clinical parameters using databases like TIMER 2.0, GIPIA 2, and UALCAN

Functional Impact Assessment:

• Implement TERF2IP knockdown using siRNA in cancer cell lines

• Confirm knockdown efficiency via Western blot

• Measure effects on cancer cell properties using established assays:

  • Cell viability (CCK-8 assay)

  • Colony formation capacity

  • Migration potential (transwell and scratch wound healing assays)

Immune Infiltration Analysis:

• Compare TERF2IP expression with immune cell infiltration profiles

• Use algorithms like TIDE, XCELL, MCPCOUNTER, and EPIC for analysis

• Focus on correlations with cancer-associated fibroblasts in BLCA, CESC, HNSC, PAAD, SKCM, and STAD cancers

• Note the negative correlation with lymphocyte infiltration in GBM, LGG, and UCS tumors

This integrated approach has demonstrated TERF2IP's potential role in modulating the tumor microenvironment across multiple cancer types.

How can researchers investigate TERF2IP post-translational modifications using specific antibodies?

Investigating TERF2IP post-translational modifications requires specialized methodological approaches:

Phosphorylation Analysis:

• Use phospho-specific antibodies or general TERF2IP antibodies followed by phosphatase treatment

• Focus on the TERF2IP phosphorylation site mentioned in transcriptome studies

• Implement kinase inhibitors (particularly targeting p90RSK) to study regulatory mechanisms

Experimental Design for PTM Mapping:

• Immunoprecipitate TERF2IP using validated antibodies

• Analyze by mass spectrometry to identify phosphorylation, ubiquitination, or other modifications

• Generate site-specific mutants of TERF2IP (particularly the phosphorylation site mutants)

• Perform functional assays comparing wild-type and mutant proteins

Subcellular Distribution Analysis:

• Use subcellular fractionation followed by Western blot

• Compare PTM patterns between nuclear and cytoplasmic fractions

• Use GAPDH and histone H3 as loading controls for cytoplasmic and nuclear fractions, respectively

Stimulus-Response Studies:

• Treat cells with DNA damaging agents, replication stress inducers, or senescence triggers

• Monitor changes in TERF2IP modifications using immunoblotting

• Correlate with functional consequences like protein interactions or telomere maintenance

These approaches can reveal how post-translational modifications regulate TERF2IP's diverse functions in telomere protection and transcriptional regulation.

What are common challenges with TERF2IP antibodies and their methodological solutions?

These solutions have been empirically validated in published TERF2IP research and provide a systematic approach to overcoming common technical challenges.

How can researchers optimize detection of TERF2IP in challenging tissue samples?

For improved TERF2IP detection in difficult tissue samples, implement these methodological refinements:

Antigen Retrieval Optimization:

• Test multiple antigen retrieval methods:

  • TE buffer at pH 9.0 (primary recommendation)

  • Citrate buffer at pH 6.0 (alternative approach)

• Optimize retrieval time and temperature (typically 95-100°C for 15-20 minutes)

Antibody Selection and Preparation:

• Choose antibodies raised against conserved TERF2IP epitopes

• Consider using a cocktail of antibodies targeting different regions

• Pre-absorb antibodies with non-specific proteins to reduce background

Signal Amplification:

• Implement tyramide signal amplification for low-abundance detection

• Use biotinylated secondary antibodies with streptavidin-HRP systems

• Consider polymer-based detection systems for enhanced sensitivity

Sample Preparation Refinements:

• Optimize fixation duration (10% neutral buffered formalin for 24-48 hours)

• Use freshly cut sections (4-5 μm thickness optimal)

• Minimize storage time of cut sections before staining

• Include positive control tissues with known TERF2IP expression

Counterstaining and Imaging:

• Use minimal hematoxylin counterstaining to avoid masking specific signals

• Implement multispectral imaging to distinguish true signal from autofluorescence

• Document all optimization steps to ensure reproducibility

These approaches have been successfully applied in cancer tissue samples from multiple organs, as referenced in immunohistochemistry protocols .

How can TERF2IP antibodies contribute to understanding telomere dysfunction in disease models?

TERF2IP antibodies enable mechanistic investigation of telomere dysfunction through these methodological applications:

Mouse Model Analysis:

• Generate EC-specific TERF2IP knockout mice as described in published protocols

• Maintain mice under approved protocols in temperature-controlled rooms with 12-h light/dark cycles

• Use TERF2IP antibodies for protein expression verification in tissue-specific knockouts

• Compare telomere integrity between wild-type and knockout tissues

Chromatin Immunoprecipitation (ChIP):

• Use TERF2IP antibodies to immunoprecipitate chromatin

• Analyze telomeric DNA enrichment by qPCR or sequencing

• Compare TERF2IP occupancy at telomeres in normal versus disease states

• Correlate with other shelterin components (especially TRF2)

Protein Complex Analysis:

• Implement co-immunoprecipitation with TERF2IP antibodies

• Identify alterations in shelterin complex composition in disease models

• Focus on TRF2-TERF2IP interaction, which is crucial for telomere maintenance

• Analyze how TERF2IP depletion affects DNA topoisomerase regulation at telomeres

Telomere Dysfunction Phenotypes:

• Use immunofluorescence to correlate TERF2IP localization with telomere dysfunction markers

• Analyze DNA damage response activation at telomeres in TERF2IP-depleted cells

• Quantify telomere abnormalities (fragility, fusions) in relation to TERF2IP levels

These approaches have revealed that TERF2IP and TRF2 are essential for controlling DNA topoisomerases during telomere replication, preventing aberrant telomere topology .

What innovative methods combine TERF2IP antibodies with genomic approaches for comprehensive telomere research?

Advanced telomere research integrates TERF2IP antibodies with genomic methods through these innovative protocols:

ChIP-sequencing Analysis:

• Perform chromatin immunoprecipitation with TERF2IP antibodies

• Prepare libraries for next-generation sequencing

• Apply bioinformatic analysis to identify:

  • Telomeric binding patterns

  • Non-telomeric binding sites

  • Relationship with transcriptional regulation

RNA-immunoprecipitation (RIP):

• Use TERF2IP antibodies to immunoprecipitate RNA-protein complexes

• Analyze associated RNAs by sequencing or qRT-PCR

• Focus on telomeric repeat-containing RNA (TERRA) interactions

• Correlate with telomere maintenance mechanisms

Proximity Ligation Assay (PLA):

• Combine TERF2IP antibodies with antibodies against interaction partners (TRF2, MLL2, p65)

• Visualize specific protein-protein interactions at single-molecule resolution

• Quantify interaction frequencies in different cell states

• Correlate with transcriptional activity and telomere functionality

Integration with Transcriptome Analysis:

• Perform TERF2IP knockdown via siRNA as described in protocols

• Conduct unbiased transcriptome analysis using RNA-seq

• Generate differential expression profiles using tools like Qlucore Omics Explorer

• Perform principal component analysis at stringent statistical thresholds (p = 3.3e-5)